Skip to content
September 21, 2026
  • Home
  • About us
  • Contact us
  • Newsletter
  • Privacy Policy
Political Economist

Political Economist

A liberal News reporting Politics, Sports, Business, Commentaries

  • Home
  • National News
    • Metro News
      • metro
    • Society
    • Crime and Justice
  • Special Reports
    • Investigation
    • Features
    • Interviews
  • Opinion
    • Commentaries
    • Perspectives
  • Press Releases
  • International News
  • Business & Economy
  • Politics
Watch Online
  • Home
  • International News
  • COVID-19: WHO temporarily suspends trial of Hydroxychloriquine as treatment 
  • International News

COVID-19: WHO temporarily suspends trial of Hydroxychloriquine as treatment 

Admin May 26, 2020
programme

WHO logo

The World Health Organization said on Monday that it had “temporarily” suspended clinical trials of hydroxychloriquine as a potential treatment for COVID-19 being carried out across a range of countries as a precautionary measure.

The decision came after the publication last week of a study in the Lancet indicating that using the drug on COVID-19 patients could increase their likelihood of dying, WHO chief Tedros Adhanom Ghebreyesus told a virtual press conference.

Tedros said that the executive group of the so-called Solidarity Trial, in which hundreds of hospitals across several countries have enrolled patients to test several possible treatments for the novel coronavirus, had as a precaution suspended trials using that drug.

“The Executive Group has implemented a temporary pause of the hydroxychloroquine arm within the Solidarity Trial while the safety data is reviewed by the Data Safety Monitoring Board,” Tedros said.

“The other arms of the trial are continuing,” he stressed.

Hydroxychloroquine is normally used to treat arthritis but pronouncement from public figures including US President Donald Trump — who announced last week he is taking the drug — has prompted governments to bulk buy the medicine.

Brazil’s health minister also recommended last week using hydroxychloroquine, as well as the anti-malarial chloroquine, to treat even mild COVID-19 cases.

The Lancet study found that both drugs can produce potentially serious side effects, particularly heart arrhythmia.

And neither drug benefited patients hospitalised with COVID-19, according to a Lancet study, which looked at the records of 96,000 patients across hundreds of hospitals.

Tedros stressed Monday that the two drugs “are accepted as generally safe for use in patients with autoimmune diseases or malaria.”

WHO chief scientist Soumya Swaminathan meanwhile told Monday’s briefing that the WHO-backed Solidarity Trial had been looking only at the effects of hydroxychloroquine and not chloroquine.

The decision on suspending enrolment for trials using hydroxychloroquine was “a temporary measure”, she said.

“We’re just acting by precaution,” WHO emergencies chief Michael Ryan agreed

AFP

  • Facebook
  • Share on X
  • LinkedIn
  • WhatsApp
  • Email
  • Copy Link

Post navigation

Previous Herders protest as Delta issues 7 days ultimatum to vacate community
Next Latvia to launch Google-Apple friendly coronavirus contact tracing app

Related Stories

Ugandan Shilling, Cedi and Kwacha Expected to Face Pressure; Nigeria and Kenya Currencies Stable
  • International News

Ugandan Shilling, Cedi and Kwacha Expected to Face Pressure; Nigeria and Kenya Currencies Stable

September 17, 2026
Oil slips as Saudi Arabia offers more crude via Oman; diesel near record high reserves crude oil
  • Business & Economy
  • International News

Oil slips as Saudi Arabia offers more crude via Oman; diesel near record high

September 16, 2026
Trump ⁠⁠⁠⁠⁠promises $5,000 to every U.S. adult if Republicans win midterm elections
  • International News

Trump ⁠⁠⁠⁠⁠promises $5,000 to every U.S. adult if Republicans win midterm elections

September 10, 2026
logo

Political Economist is a liberal news magazine with global affiliations.

At Political Economist, we promote free enterprise and act as a catalyst for the growth of knowledge economy. We are proudly pan-Nigeria yet richly spiced with African and global news. We offer a fair and balanced news reportage presented by our team of well-heeled professional journalists. <

About us

  • 5 Olutosin Ajayi Street, By CPM Church, Ajao Estate, Lagos State, Nigeria
  • +234 805 680 1124
  • info@politicaleconomistng.com

Follow

Subscribe to notifications

You may have missed

Tinubu hails winners of by-elections in Gombe, Kano, Bauchi and Delta states
  • Politics

Tinubu hails winners of by-elections in Gombe, Kano, Bauchi and Delta states

September 20, 2026
PROPOSED PETROL SUBSIDY: Tinubu Campaign Council demands breakdown from Atiku
  • National News

PROPOSED PETROL SUBSIDY: Tinubu Campaign Council demands breakdown from Atiku

September 20, 2026
Shettima to declare NGE conference open in Enugu Thursday
  • National News

Shettima to declare NGE conference open in Enugu Thursday

September 20, 2026
Osimhen ​‌‌‌⁠‍‍⁠⁠‌⁠‌​​​​‍⁠‌​ruled out of Nigeria’s AFCON qualifiers as muscle injury lingers
  • National News

Osimhen ​‌‌‌⁠‍‍⁠⁠‌⁠‌​​​​‍⁠‌​ruled out of Nigeria’s AFCON qualifiers as muscle injury lingers

September 20, 2026
  • Home
  • About us
  • Contact us
  • Newsletter
  • Privacy Policy
Copyright © All rights reserved. | DarkNews by AF themes.